Pertuzumab

帕妥珠单抗

Report date: 2023/11/16 16:50:47

Base Information

Drug NamePertuzumab
Drug Alias Name培妥珠单抗Anti-2C4 monoclonal antibodyPertuzumabum珀妥珠单抗帕妥株单抗 +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Metastatic breast cancerGastroesophageal Junction Neoplasms +[22] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2012/06/08
Country/TerritoryCzechiaBahamasBelgium +[71] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMabscale LLCChugai Pharmaceutical Co LtdRoche Pharma (Schweiz) Ag +[9] 
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Roche Pharma AgF. Hoffmann-La Roche Ag +[6] 
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursNeoplasm Metastasis +[5] 
Inactive IndicationsPancreatic neuroendocrine tumors (pNET)Metastatic breast cancerProstatic Neoplasms +[17] 

Other Information

ATC CodeL01FD02L01XC13
Related LinksWikipediaDrugBankKEGG